FORO DE I D BIOMEDICA GLOBAL - PowerPoint PPT Presentation

Loading...

PPT – FORO DE I D BIOMEDICA GLOBAL PowerPoint presentation | free to download - id: 7dfdb-YWJhM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

FORO DE I D BIOMEDICA GLOBAL

Description:

FORO DE I D BIOMEDICA GLOBAL. LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: ... Institute of Neurosciences of Alicante. INA, Alicante ... – PowerPoint PPT presentation

Number of Views:47
Avg rating:3.0/5.0
Slides: 22
Provided by: lthe
Learn more at: http://www.fundsis.org
Category:
Tags: biomedica | foro | global

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: FORO DE I D BIOMEDICA GLOBAL


1
FORO DE ID BIOMEDICA GLOBAL
LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA
CHINA, SINGAPUR Y COREA DEL SUR
STRENGHTS, CHALLENGES AND DRIVERS OF THE
CHINESE BIOSCIENCES AND BIOTECH GROWTH
Carlos Martinez-A
2
Communicating biotech ....
BioPlastic is plastic BioDiesel is diesel.
Corn is corn Soya is soya
Medicines are medicines
3
European Biotech Industry ?
Here?
Here?
Here?
Here?
Here?
Here?
Follow on
Pre-seed
Seed
VC
IPO
Debt
Or along the capital pipeline?
4
European Biotech Industry
  • Fragmentation ? lack of critical mass
  • Product markets
  • Financial markets
  • Regulatory frameworks
  • Centers of excellence and clusters
  • Business attitude
  • Political attitude
  • 10-year gap
  • Lack of all forms of finance

5
European Biotech Industry
Source Critical I and EuropaBio
6
European Biotech Industry
Source Critical I and EuropaBio
7
European Biotech Industry
8
European Biotech Productivity
  • La productividad de las biotech es superior a la
    de las farmacéuticas

Fuente Ernst Young, Beyond Borders (Biotech
Report), Nov 2005
9
European Biotech Productivity
  • Durante el 2005 las compañías de biotecnología
    han experimentado una rentabilidad superior a las
    Farmacéuticas y a los principales índices

Fuente Bloomberg, Abn Amro
10
European Biotech Productivity
European Biotech Industry
Valor de capitalización bursátil (miles de
millones de dólares)
Programas en fase clínica (Numero de programas)
958
343,3
334,9
Fase II/III
110
Fase I
Fase II/III
Fase I
Pfizer y Glaxosmithkline
World Biotech Sector
Pfizer y Glaxosmithkline
World Biotech Sector
  • … En su conjunto el valor de capitalización
    bursátil del sector es igual al valor bursátil de
    Pfizer y GSK …. con 8 veces el potencial de
    crecimiento

Fuente GS Global research 2003, SG Cowen
Pipeline Plus March 2004, BB Biotech
11
European Biotech Industry
Political risks
VALUE
RD risks
IP risks
Financing risks
Regulatory risks
RISK
Market risks
TIME
12
European Biotech Industry
VALUE
RD risks
Political risks
IP risks
Financing risks
Regulatory risks
RISK
Market risks
TIME
13
Ingenio 2010
The Spanish Government has presented the INGENIO
2010 program to stimulate RDi
  • Reach 2 of the GDP for RD in 2010 and 1.5 in
    2007
  • Reach 55 private contribution in RD investment
    in 2010
  • Achieve the EU mean in the percentage of the GDP
    assigned for TIC, to go from 4.8 in 2004 to 7
    in 2010

OBJECTIVES
Budget 8.000 M
  • CENIT public-private collaboration
  • CENIT projects
  • Fund of Capital Risk funds
  • Torres Quevedo Program
  • Increased the number of spin-offs by four folds
  • CONSOLIDER increase critical mass and
    researcher excellence
  • Avanz_at_ convergence of the EU with the
    Information Society

INSTRUMENTS
14
CSIC over 60 years devoted to RD
1907 Council for the Extension of Studies and
Scientific Research
Santiago Ramón y Cajal The Nobel Prize in
Physiology or Medicine 1906
Severo Ochoa The Nobel Prize in Physiology or
Medicine 1959
15
CSIC over 60 years devoted to RD
  • Performing
  • Multidisciplinary Scientific and Technological
    Research
  • Scientific and Technical Assessments
  • Training of scientific and technical personnel
  • Management of infrastructures
  • Collaborating with
  • Universities
  • Other public RD Organisations
  • Industries
  • Enterprises, Professional
  • Associations and Foundations
  • Regional Governments

16
Budget Human Resources
BUDGET
TOTAL BUDGET ?530 M
MEC
61,5
38,5
External resources
17
CSIC Institutes in the Scientific Area of Biology
and Biomedicine
Andalusian Center of Developmental Biology. CABD,
Sevilla Andalusian Center of Molecular Biology
and Regenerative Medicine. CABIMER,
Sevilla Center of Cardiovascular Research. CIC,
Barcelona Center for Regenerative Medicine, CMR,
Barcelona Center of Biological Research. CIB,
Madrid National Center of Biotechnology. CNB,
Madrid Institute of Molecular and Cellular
Biology Primo Yúfera. IBMCP, Valencia Institute
of Molecular and Cellular Biology of Cancer.
IBMCC, Salamanca Institute of Molecular Biology
of Barcelona. IBMB, Barcelona Laboratory of Plant
Genetics-IBMB. Barcelona Center of Molecular
Biology, CBM, Madrid Institute of Biology and
Molecular Genetics. IBGM, Valladolid Institute of
Biomedicine of Valencia. IBV, Valencia Institute
of Plant Biology and Photosynthesis. IBVF,
Sevilla Institute of Biomedical Research Alberto
Sols. IIB, Madrid Institute of Biomedical
Research of Barcelona. IIBB, Barcelona Institute
of Biochemical Microbiology. IMB,
Salamanca Institute of Neurobiology Ramón y
Cajal. INRC, Salamanca Institute of
Neurosciences of Alicante. INA,
Alicante Institute of Parasitology and
Biomedicine López Neyra. IPBLN, Granada Unit of
Biophysics. UBF, Bilbao
21 Research Centers
18
RECURSOS ECONÓMICOS
19
KNOWLEDGE TRANSFER
EMPRESAS DE BASE TECNOLÓGICA
20
CSIC Asia Collaboration
CSICs Subscribed Agreements
CHINA Chinese Academy of Sciences (CAS) National
Natural Science Foundation (NSFC)
Bottom-up approach
JAPAN Japan Society for the Promotion of Science
(JSPS)
Republic of KOREA Korea Science and Engineering
Foundation (KOSEF)
Joint projects and exchange of researchers
TAIWAN National Science Council (NSC)
VIETNAM Vietnamese Academy of Science and
Technology (VAST)
21
Thank you! Gracias!
About PowerShow.com